Matches 1 - 50 out of 86 1 2 >


Match Document Document Title
DE102017125166A1 Detumescence-ODYNOLYSE OINTMENT  
The present invention provides a detumescent odynolysis ointment having good overall pharmaceutical properties and good treatment effect, is made by using Rhizoma alismatis as a main raw material,...
DE102018000009A1 drug  
According to the invention a pharmaceutical is disclosed, a.) Containing carboxymethylated starch and b.) Containing a citrate and / or citric acid for the reduction of postoperative adhesions.
DE102007063902B3 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being an aptamer that binds to activated protein C, the aptamer having a dissociation constant KD binds to activated...
DE102009017015B4 Process for the preparation of an adhesive hemostatic agent based on pig atelocollagen  
A method of making a collagen-based adhesive hemostatic agent which includes: a) removal of immunogenic telopeptides from pig collagen by enzyme treatment to produce atelocollagen; b) reacting an...
DE102014111892A1 Prophylaxis and treatment of infection by the hantavirus  
The present invention relates to an inhibitor for the prophylaxis and treatment of infection of a living being with a hantavirus and to a pharmaceutical composition containing the inhibitor.
DE102013222223A1 Hemostatic agent containing crystalline polyphosphate  
The present invention relates to the use of polyphosphate in crystalline form for the treatment of wounds, in particular bleeding wounds, the anion of the polyphosphate having on average (number...
DE102011007891A1 New ring-fused 4-aminopyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease and renal insufficiency  
Ring-fused 4-aminopyrimidine compounds (I) and their N-oxides, salts, solvates, salts of N-oxides or solvates of N-oxides and salts, are new. Ring-fused 4-aminopyrimidine compounds of formula (I)...
DE102011007890A1 New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency  
Fluoroalkyl-substituted pyrazolopyridine compounds (I) are new. Fluoroalkyl-substituted pyrazolopyridine compounds of formula (I) and their N-oxides, salts, solvates, salts of N-oxides and...
DE102011013326A1 New fibrinolysis inhibitors and their use mdizinische  
Fibrinolysis inhibitors and their medical use for antifibrinolytic therapy and prophylaxis. Known fibrinolysis inhibitors are used in surgical procedures that have greater intraoperative or...
DE102009029717A1 Medical product, useful for post-surgical adhesion prophylaxis and/or hemostasis, comprises physically crosslinked polyvinyl alcohol and at least one biocompatible nucleating agent  
Medical product comprises physically crosslinked polyvinyl alcohol and at least one biocompatible nucleating agent. An independent claim is included for method for producing the medical product...
DE202009015258U1 Agents and hygienic product for the prevention of hemorrhoids and eliminating skin irritation  
Means for prevention of hemorrhoids and eliminating skin irritation, characterized in that it contains the following ingredients: Distilled glycerin, oil extract of burdock herb hydro alcoholic...
DE102008032361A1 The use of Factor VIII and vWF or vWF concentrates containing the treatment of induced platelet inhibitors coagulopathy  
The invention relates to the administration of coagulation factor VIII and von Willebrand factor (vWF) or medication alone vWF containing for therapeutic use in the induced platelet inhibitors...
DE102008020197A1 Quickly wettable, hydrocolloid-containing material, process for its preparation and its use  
The present invention relates to a method for producing a quick-wettable, hydrocolloid-containing material in which a hydrocolloid-containing material is exposed to a plasma.
DE4407386B4 Process for reactivating purified membrane proteins by freezing  
process for reactivation of membrane proteins, characterized in that that a membrane protein frozen in the presence of a lipid and a detergent and The frozen thawed again and the reaction mixture...
DE102006050672A1 New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations  
Glycylglycine derivatives with a benzylsulfonylamido group at one end of the chain and an amidino-organylamido group at the other end are new, including their racemates, crystal forms, hydrates...
DE4435392B4 Process for separating vWF into high molecular vWF and low molecular vWF  
process for separating vWF into high molecular vWF and low molecular weight vWF, characterized in that - VWF binds to an affinity support, - As a buffer system for the affinity a Ca2+-free buffer...
DE102006042615A1 Liquid medicament preparation, useful for treating vitamin-K-deficiency condition, comprises phytomenadione, polysorbate, sorbic acid, chelating agent and edetate sodium for stabilizing dissolved phytomenadione  
Phytomenadione containing liquid medicament preparation for oral application, comprises phytomenadione, polysorbate 80, sorbic acid and purified water as chelating agent and additionally 0.01%...
DE10303229B4 Ambroxol and inhibitors of the angiotensin converting enzyme (ACE) pharmaceutical compositions comprising drug preparation and their use for the treatment of neurodegenerative diseases  
Pharmaceutical Preparations consisting of ambroxol or its salts and at least an inhibitor of angiotensin converting enzyme, and in addition usual pharmaceutically acceptable carriers, Additives...
DE102005023666A1 Use of marmot oils for the treatment of skin diseases such as acne vulgaris, acne rosacea, neurodermitits, phlebitis, herpes or external hemorrhoids  
Use of marmots oil for the treatment of skin diseases. An independent claim is included for a topical dermatological composition comprising the marmot oil. ACTIVITY : Antiseborrheic;...
DE19952957B4 Modular Transport systems for molecular substances and their production and use  
transport system for molecular Substances containing recombinantly produced partial units Amino acid-based, having the following characteristics: - At least two mutually simply different partial...
DE60115613T2 PRODUCTION OF RECOMBINANT muteins OF COAGULATION FACTOR VIII IN HUMAN CELL LINES  
The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX. An immortalized human cell line can...
DE102004031343A1 Medicine-technical auxiliary agent, useful to treat hemorrhoids, comprises a combination of bitter clover, king herb, liver herb, passion herb, sorrel, yarrow, plantain, chicory (all dried) and salt less lard  
A medicine-technical auxiliary agent (I), for the treatment hemorrhoids, comprising a combination of salt less lard (1 kg), bitter clover (dried) (20 g), King herb (dried) (10 g), liver herb...
DE102004037805B3 Heat treatment process for fibrinogen pharmaceutical preparations  
It a method for reduction of aggregate formation in the Heat treatment of fibrinogen-aqueous solutions is described in which the fibrinogen solution in addition to customary...
DE102004009400A1 fibrinogen cleaning  
The This invention relates to a process for the purification of fibrinogen, characterized in that it comprises one or more process steps contains, in which one or more contaminating proteins by...
DE19833476B4 Genetically modified CD34-negative adherently growing haematopoietic stem cells and their use in gene therapy  
Genetically Modify CD34-negative adherently growing hematopoietic Stem cells.
DE202004010172U1 Composition for treating hemorrhoids comprises unsalted lard and selected dried herbs  
Composition for treating hemorrhoids comprises unsalted lard (1 kg) and the following dried herbs: buck bean (20 g), field basil (10 g), hepatica (20 g), passion flower (30 g), sorrel (15 g),...
DE10303229A1 α-lipoic acid, ambroxol and / or inhibitors of the angiotensin converting enzyme (ACE) comprehensive drug preparation and their use for the treatment of neurodegenerative diseases  
The present invention relates to the use of a combination of drugs for the prevention and therapy of neurodegenerative diseases (eg. As ischemic and hemorrhagic stroke, focal and global ischemia,...
DE10246125A1 Concentrate of a factor VIII: C-containing von Willebrand factor and the associated method  
The invention relates to a concentrate and a process for the production of a Factor VIII: C-containing von Willebrand factor by frkationierte precipitation from a Factor VIII: C and the liquid...
DE10261126A1 Storage stable, liquid fibrinogen formulation  
The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form, containing divalent metal ions. The fibrinogen formulation may further...
DE10309368A1 Pharmaceutical formulation having RNA as a cofactor of haemostasis  
It pharmaceutical preparations are described which contain the promotion of blood coagulation as well as for the promotion of fibrinolysis sufficient quantities of RNA or one or more...
DE10229379A1 Treatment and prevention of endometrial disease, e.g. endometriosis or carcinoma, by inhibiting endocrine gland vascular endothelial growth factor, also diagnosis  
A composition that contains, as active agent (A), an endocrine gland vascular endothelial growth factor (EG-VEGF) nucleic acid, polypeptide or antisense nucleic acid, antibody against EG-VEGF or...
DE10227269A1 thiazole  
Thiazole derivatives of the formula I where R1, R2, R3, V, W, X and B have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be used for treatment of osteoporosis,...
DE10225574A1 New 1-acyl-3-phenyl-5,6-dihydro-4H-pyridazine derivatives, are phosphodiesterase IV inhibitors useful e.g. for treating asthma, allergy, inflammation, autoimmune diseases or myocardial diseases  
1-((Hetero)aralkylideneiminooxy-alkanoyl)-3-phenyl-5,6-dihyd ro-4H-pyridazine derivatives (I) are new. Pyridazine derivatives of formula (I) and their derivatives, solvates, stereoisomers and E/Z...
DE10163991A1 Pyrrolo-pyrimidines  
The invention relates to pyrrolopyrimidine derivatives of formula (I), wherein R<3>, R<4>, R<5>, R<6> and X are defined as per claim 1. Said derivatives act as phosphodiesterase VII inhibitors and...
DE10148883A1 New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors  
Benzylamino or pyridylmethylamino-substituted furo- or pyrrolo-pyrimidine derivatives (or tricyclic analogs) (I) are new. Fused pyrimidine derivatives of formula (I) and their derivatives,...
DE10058461A1 Substituted cyclohexane derivatives and their use  
The present invention relates to substituted cyclohexane derivatives of the formula (I), processes for their preparation and their use in medicaments, in particular for the prevention and / or...
DE10044792A1 Substituted Phenylcyclohexancarbonsäureamide and their use  
The present invention relates to substituted Phenylcyclohexancarbonsäureamide of formula (I), processes for their preparation and their use in medicaments, in particular for the prevention and /...
DE10045047A1 Medicaments containing activated antithrombin III  
The invention relates to the use of antithrombin III, which is modified in the conformation thereof and which is cited in the description as activated antithrombin III (IDAAT = immune defense...
DE10043124A1 A method for diagnosis of neuronal diseases and for the treatment of primary hemostasis deficiency  
The invention relates to a method for diagnosing neuronal diseases and for treating primary hemostasis deficiency. The invention further relates to a method for suppressing the immune system,...
DE10035144A1 Cyclic amino acid derivatives  
Novel compounds of formula (I), wherein R<1>, R<2>, R<2'>, R<2''>, R<3>, R<4>, R<5>, R<5'>, R<5''>, R<5'''>, R<5''''>, X, Y, U, V and W have the meanings given in claim no.1, are inhibitors of the...
DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma  
8 beta -Substituted 11 beta -(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives (I) are new. 8 beta -Substituted 11 beta -(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives of formula (I) are...
DE10012732A1 Thrombin composition, for use as hemostatic or as a component of fibrin glues, comprises non-covalently bonded inhibitor for stabilization  
Thrombin composition, (A,) that contains a non-covalently bonded inhibitor (I) as stabilizer, is new. Independent claims are also included for the following: (1) preparing a thrombin composition...
DE19958153A1 Oxazolidinone derivatives  
Compounds of formula (I), wherein R<1>, R<2> and n have the meanings give in claim N DEG 1, and their physiologically compatible salts and solvates can be used as GP IIbIIIa antagonists for...
DE19952957A1 Modular Transport systems for molecular substances and their production and use  
The invention relates to transport systems for molecular substances, comprising a mosaic of recombinant partial units (individual components). The invention further relates to production of the...
DE19947010A1 The gene PRV-1 and its use  
The invention relates to a necleotide sequence which codes for the PRV-1 protein and which essentially comprises the ID sequence N DEG .1. The invention also relates to a method for detecting this...
DE19937219A1 A process for the purification of the blood clotting factor VII-activating protease, its proenzyme or a mixture of both proteins by ion exchange chromatography  
It is a process for the purification of the blood clotting factor VII-activating protease and / or its proenzyme is described in which these resulting from biological or in the genetic engineering...
DE19937218A1 A process for the purification of the blood clotting factor VII-activating protease, its proenzyme or a mixture of both proteins by affinity chromatography  
It is described by applying one or more affinity chromatographic separation process and / or a fractional precipitation to a process for purification of the blood clotting factor VII-activating...
DE19915862A1 Using molekulargewichtserweitertem hirudin as an anticoagulant in extracorporeal renal replacement therapy  
The invention relates to the use of molecular weight-amplified hirudin in order to produce an anticoagulant, which does not induce any type of autoimmune disease and which does not cross-react...
DE19856668A1 Active substance matrix in the form of a bioabsorbable porous web, to processes for their preparation and use  
The invention relates to an active ingredient matrix in the form of a biologically resorbable porous non-woven made of collagen fibrils in a dry frozen state with delayed release of said active...
DE19847823A1 New 3-(Hetero)aryl-5-aminosulfonyl-1,2,4-thiadiazole derivatives useful as inhibitors of IL-1beta production in treatment of e.g. leukemia, septic shock, hepatitis, AIDS and diseases of locomotor system  
3-(Aryl or heteroaryl)-5-aminosulfonyl-1,2,4-thiadiazole derivatives are new. 3-(Aryl or heteroaryl)-5-aminosulfonyl-1,2,4-thiadiazole derivatives of formula (I) and their stereoisomers and salts:...

Matches 1 - 50 out of 86 1 2 >